- Regulatory Status
- RUO
- Other Names
- SIGLEC2, CD22 Antigen, BL-CAM, B-Cell Receptor CD22
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Save |
---|---|---|---|
797604 | 25 µg | ¥57,320 | |
797606 | 100 µg | ¥170,350 |
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
CD22 is a type I transmembrane protein of 140 kD expressed in B cells. The extracellular domain (ECD) contains seven Ig domains with 12 recognized N-linked glycosylation sites. CD22 binds to α2,6-linked sialic acid (Sias) ligands connected to galactose. The Ig domain 1 (d1) recognizes Sias containing α2,6-linkages. CD22 regulates signaling through its intracellular inhibitory ITIMs domains. The regulation of B cell function by CD22 is performed through sialic ligand-dependent and -independent mechanisms. CD22 regulates the migration of recirculating B cells to the bone marrow. CD22 knockdown mice present B cell impaired survival, increase of B cell turnover, and decrease of marginal zone B cells. In addition, CD22-deficient B cells show hyperactivation in response to TLR (TLR3, TLR4, and TLT9) ligands. CD22 ligation with anti-CD22 affects the response to TLR7. Under this condition, the B cell differentiation into plasmablasts is limited, and the B cell production of cytokine by the stimulation of TLR7 or TLR9 is affected. B-cell leukemias and lymphomas express CD22, and it has been used as a target for Ab-dependent therapies. Epratuzumab (Emab) is a humanized anti-CD22 used in clinical trials of B-cell Non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Emab has been explored in clinical trials for SLE and primary Sjogren’s syndrome.
Product DetailsProduct Details
- Source
- Human CD22-Fc, amino acid (Asp20 – Arg687) (Accession: P20273), with a C-terminal human IgG1 (Pro100-Lys330), and an Avi-tag, was expressed in CHO cells. Human CD22-Avi tag was site-specifically biotinylated by enzyme BirA.
- Molecular Mass
- The 931 amino acid recombinant protein has a predicted molecular mass of approximately 104.3 kD. The protein migrates at approximately 120 kD and 240 kD by SDS-PAGE in DTT-reduced and non-reduced conditions, respectively. The predicted N-terminal amino acid is Asp.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE
- Formulation
- 0.22 µm filtered protein solution is in PBS pH 7.2
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose dependent manner. The ED50 for this effect is 1 – 6 µg/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Dimer
- Distribution
-
B cells
- Function
- Mediates B cell/B cell interactions, regulates B cell functions, inhibitory co-receptor of BCR, regulate negatively TLRs signaling in B cells.
- Interaction
- B cells, B cell lines, DC
- Ligand/Receptor
- CD45RO, CD75
- Bioactivity
- Biotinylated recombinant human CD22-Fc chimera inhibits the proliferation of human B cells induced by LPS in a dose-dependent manner.
- Cell Type
- B cells
- Biology Area
- Adaptive Immunity, Cell Adhesion, Cell Biology, Cell Proliferation and Viability, Immuno-Oncology, Immunology, Innate Immunity
- Molecular Family
- CD Molecules, Cytokine/Chemokine Receptors, Soluble Receptors
- Antigen References
-
- Willson GL, et al. 1991. J Exp Med. 173:137-46.
- Santos L, et al. 2008. J Immunol. 180:4561-9.
- Nirihito K, et al. 2011. J Innate Immune. 3:411.
- Poe JC and Tedder TF. 2012. Trends Immunol. 33:413-20.
- Muller J, et al. 2013. Proc Natl Acad Sci USA. 110:12402-7.
- Oreno-Orbea J, et al. 2017. Nat Commun. 8:764.
- Giltiay NV, et al. 2017. Arthritis Res Ther. 19:91.
- Clark EA and Giltiay NV. 2018. Front Immunol. 9:2235.
- Gottenberg JE, et al. 2018. Arthr Rheumatol. 70:763-773.
- Gene ID
- 933 View all products for this Gene ID
- UniProt
- View information about CD22 on UniProt.org
Follow Us